NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. ("Hims & Hers Health, Inc." or the "Company") (NYSE: HIMS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Hims & Hers Health, Inc. investors who were adversely affected by alleged securities fraud between April 29, 2025 and June 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.co ...

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) that Hims was engaged in the "deceptive promotion and selling of illegitimate, ...

SAN DIEGO, Aug. 8, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, both dates inclusive (the "Class Period"), have until Monday, August 25, 2025 to seek appointment as lead plaintiff of the Hims & Hers class action lawsuit. Captioned Sookdeo v. Hims & Hers Health, Inc., No. 25-cv-05315 (N.D. Cal.), the Hims & Hers class action lawsuit charges Hims & Hers and certain of H ...

NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS). Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/hims-hers-health-inc-loss-submission-form/?id=159975&from=3 CLASS PERIOD: A ...

SAN FRANCISCO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- On August 5, 2025, investors in Hims & Hers Health (NYSE: HIMS) declined almost 11% in another sell-off after the company disclosed that it would lower revenue recognized per customer specific to its so-called personalized GLP-1 component, a medication the company compounds to treat weight loss. This disclosure comes as the company previously experienced a sell-off in its shares which triggered a securities class action lawsuit tied to a cancelled collaborati ...

Bagsværd, Denmark, 6 August 2025 - Financial report for the period 1 January 2025 to 30 June 2025                                                                                                                                                             Operating profit increased by 25% in Danish kroner and 29% at constant exchange rates (CER) to DKK 72.2 billion.Sales in US Operations increased by 16% in Danish kroner (17% at CER). Sales in the US were positively impacted by gross-to-net sales adjustments ...

集体诉讼案件 - 律师事务所Bragar Eagel & Squire宣布对Hims & Hers Health Inc提起集体诉讼 代表在2025年4月29日至6月23日期间购买或获得该公司证券的所有个人和实体 [1] - 投资者需在2025年8月25日前向法院申请成为主要原告 [1] 指控内容 - 指控被告在集体诉讼期间做出重大虚假或误导性陈述 并隐瞒有关公司业务、运营和前景的重大不利事实 [3] - 具体指控包括未披露Hims推广和销售非法的Wegovy仿制品 危及患者安全 导致与诺和诺德合作终止的风险增加 [3] - 指控被告关于与诺和诺德长期合作确保用户持续获得Wegovy的陈述存在虚假或误导性 包括声称诺和诺德批准Hims在"个性化"例外下提供复合司美格鲁肽产品 [4] 法律行动参与 - 鼓励在集体诉讼期间购买Hims证券并遭受损失的投资者联系律师事务所讨论法律权利 [1][5] - 提供律师事务所的联系方式 包括电话(212) 355-4648和邮箱investigations@bespc.com [5][8]

PHILADELPHIA, Aug. 5, 2025 /PRNewswire/ -- Berger Montague PC is investigating claims under the federal securities laws against Novo Nordisk A/S (NYSE: NVO) ("Novo" or the "Company"), a global pharmaceutical company, headquartered in Denmark, after a class action lawsuit was filed against Novo.Investor Deadline: Investors who purchased or acquired Novo securities between May 7, 2025 through July 28, 2025 (the "Class Period"), may, no later than September 30, 2025, seek to be appointed as a lead plaintiff re ...

PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC announces a class action lawsuit against Novo Nordisk A/S (NYSE: NVO) (“Novo” or the “Company”) on behalf of investors who purchased or otherwise acquired publicly traded securities of Novo from May 7, 2025 through July 28, 2025 (the “Class Period”). Investor Deadline: Investors who purchased or acquired Novo securities during the Class Period may, no later than September 30, 2025, seek to be appointed as a lead ...

诺和诺德终止与Hims & Hers合作 - 丹麦制药公司诺和诺德于2025年6月23日终止与Hims & Hers的合作关系 原因为对其销售策略和"欺骗性"营销Wegovy®减肥药的担忧 [1] - 合作始于2025年4月29日 涉及在Hims & Hers平台销售诺和诺德FDA批准的Wegovy® 但不到两个月即终止 [5] - 诺和诺德指控Hims & Hers违反美国法规 大规模销售复合版本品牌药物 并以"个性化"为幌子 [5] 法律诉讼与投资者索赔 - 证券集体诉讼针对Hims & Hers及部分高管 涉及2025年4月29日至6月23日期间购买公司证券的投资者 [2] - 诉讼指控公司向投资者作出误导性保证 包括监管合规性 GLP-1药物收入稳健性 以及与诺和诺德合作带来的"顺风" [6] - 原告声称公司未披露关键业务信息 涉及推广和销售未经授权的Wegovy®仿制药 使患者面临未知风险 [7] 立法者呼吁打击仿制药市场 - 2025年7月25日 超过80名两党立法者要求FDA制止GLP-1药物的假冒和仿制版本 表达对非法和假冒抗肥胖药物激增的担忧 [4] - 立法者回应指出这些药物"增加患者安全风险 有时会导致致命后果" [4] 公司声明与实际情况矛盾 - Hims & Hers在2025年2月24日第四季度财报电话会议上保证"将继续监测并遵守与GLP-1短缺相关的监管要求" 但诺和诺德的指控与此矛盾 [5] - 调查重点为公司是否误导投资者关于营销Wegovy®仿制药的风险 这些行为可能危及患者和与诺和诺德的合作 [8]